Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time for Big pharma to take a run!

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Feb 19, 2021 7:59am

154 Views

Post# 32607288

RE:Time for Big pharma to take a run!

Hey 2burtc, though I am on the long side of ATE, I don't agree with you when you say "not because mgmt needed money". While we need attract more attention from investors, misleading them can never be the right way. It is completely illogical to dilute not because the company needs money.

3burtc wrote: Bought deal could be done for many reasons, but not because mgmt needed money. My guess is big pharma will throw an offer at shareholders anytime soon. Watch,wait, grab beer and popcorn and enjoy the stockhouse national Enquirer.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China